Scholarlink

Objective <p>Clear cell carcinoma of the cervix (CCC) is a rare, aggressive, HPV-independent subtype of cervical carcinoma. This study aimed to evaluate the clinicopathologic characteristics, treatment patterns, and survival outcomes of patients diagnosed with CCC at a tertiary cancer centre over a decade.</p> Methods <p>We retrospectively analysed 17 patients diagnosed with CCC between 2012 and 2024. Data were extracted from medical records, including clinical presentation, histopathological features, treatment modalities, and outcomes. Diagnosis was confirmed through histology and immunohistochemistry using markers such as Napsin A. Patients were staged using the 2019 FIGO system and treated following protocols for squamous cell carcinoma. Survival analysis was performed using Kaplan-Meier estimates, and prognostic factors were evaluated via Cox regression analysis.</p> Results <p>The median age at diagnosis was 52 years (range 22–65), with 29% of patients under 30 years. No cases had documented DES exposure. Most patients presented with stage II disease. Six patients underwent surgery, while 16 received radiotherapy; 10 received concurrent chemoradiation. Intracavitary brachytherapy was used in 8 patients. Median follow-up was 66 months, with a median OS of 32 months and PFS of 22 months. The 5-year OS and PFS rates were 44.66% and 35.2%, respectively. Prognosis was significantly associated with disease stage and use of concurrent chemotherapy.</p> Conclusion <p>CCC cervix remains a rare and aggressive malignancy with suboptimal outcomes. Establishing a rare tumor registry and encouraging multicenter collaboration are crucial to improve evidence-based management and support translational research.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-World Insights into Clear Cell Carcinoma of the Cervix: A Single-Institution Retrospective Study

  • 期刊论文

  • 发表日期：

    2025年12月19日

查看全文
  • G. Y. Srinivasa,
  • Vasudha Sharma,
  • Treshita Dey,
  • Venkata Krishna Vamsi Gade,
  • Manish Rohilla,
  • Nalini Gupta,
  • Bhavana Rai,
  • Subhas Chandra Saha,
  • Rashmi Bagga,
  • Vanita Jain,
  • Radhika Srinivasan,
  • Sushmita Ghoshal

摘要

Objective

Clear cell carcinoma of the cervix (CCC) is a rare, aggressive, HPV-independent subtype of cervical carcinoma. This study aimed to evaluate the clinicopathologic characteristics, treatment patterns, and survival outcomes of patients diagnosed with CCC at a tertiary cancer centre over a decade.

Methods

We retrospectively analysed 17 patients diagnosed with CCC between 2012 and 2024. Data were extracted from medical records, including clinical presentation, histopathological features, treatment modalities, and outcomes. Diagnosis was confirmed through histology and immunohistochemistry using markers such as Napsin A. Patients were staged using the 2019 FIGO system and treated following protocols for squamous cell carcinoma. Survival analysis was performed using Kaplan-Meier estimates, and prognostic factors were evaluated via Cox regression analysis.

Results

The median age at diagnosis was 52 years (range 22–65), with 29% of patients under 30 years. No cases had documented DES exposure. Most patients presented with stage II disease. Six patients underwent surgery, while 16 received radiotherapy; 10 received concurrent chemoradiation. Intracavitary brachytherapy was used in 8 patients. Median follow-up was 66 months, with a median OS of 32 months and PFS of 22 months. The 5-year OS and PFS rates were 44.66% and 35.2%, respectively. Prognosis was significantly associated with disease stage and use of concurrent chemotherapy.

Conclusion

CCC cervix remains a rare and aggressive malignancy with suboptimal outcomes. Establishing a rare tumor registry and encouraging multicenter collaboration are crucial to improve evidence-based management and support translational research.